{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:49Z","timestamp":1777870429024,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The impact of new immunosuppressive strategies to prevent graft rejection on prescribing patterns is poorly documented. The objective of this study was to describe immunosuppressive medication use and survival outcomes in patients undergoing kidney transplantation in France between 2009 and 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was performed using data from the French national healthcare database. All adult patients undergoing kidney transplantation between 2009 and 2020 were identified, and followed from transplantation until study end, death or graft failure. All immunosuppressive drug deliveries from pharmacies were documented. Survival and death-censored graft failure were estimated using Kaplan-Meier analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty four thousand six hundred kidney transplantation patients were eligible. Median follow-up duration was 4.0 years [IQR: 1.6\u20137.0 years]. Five-year survival probability was 0.890 [0.885\u20130.895], and death-censored graft survival was 0.850 [0.844\u20130.856]. Overall survival, but not graft survival was age-dependent. Calcineurin inhibitors were delivered to 29,573 patients (91.3%), antimetabolites to 29,318 (90.5%), corticosteroids to 28,536 (88.1%), mTOR inhibitors to 5231 (16.1%) and belatacept to 1272 (3.9%). The use of tacrolimus, everolimus and belatacept increased over time, while the use of corticosteroids, ciclosporin and sirolimus declined. Immunosuppressive treatment was maintained by 22,963 patients (76.5%) throughout follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this comprehensive study of kidney transplant recipients in France, we observed high rates of overall patient and graft survival. Over the study period, immunosuppressive treatment patterns were relatively stable and dominated by the use of calcineurin inhibitors. These results provide important insights into the state of post-transplant care and the potential implications of increased availability of innovative therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-025-02296-4","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T03:08:29Z","timestamp":1747105709000},"page":"1229-1237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER)\u00a0over a 12 year period"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5793-6174","authenticated-orcid":false,"given":"Dany","family":"Anglicheau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-8726","authenticated-orcid":false,"given":"Antoine","family":"Durrbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bardoulat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickael","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-4552","authenticated-orcid":false,"given":"Fran\u00e7ois-Emery","family":"Cott\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu","family":"Vadanici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2469-920X","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Chartier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-4237","authenticated-orcid":false,"given":"Denis","family":"Glotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"2","key":"2296_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2215\/cjn.05021107","volume":"3","author":"M Abecassis","year":"2008","unstructured":"Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB, Merion RM, Metzger RA, Pradel F, Schweitzer EJ, Velez RL, Gaston RS (2008) Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation\/Kidney Disease Outcomes Quality Initiative (NKF\/KDOQITM) conference. Clin J Am Soc Nephrol 3(2):471\u2013480. https:\/\/doi.org\/10.2215\/cjn.05021107","journal-title":"Clin J Am Soc Nephrol"},{"key":"2296_CR2","volume-title":"EAU Guidelines on renal transplantation","author":"A Breda","year":"2022","unstructured":"Breda A, Budde K, Figueiredo A, Lled\u00f3 Garc\u00eda E, Olsburgh J, Regele H, Boissier R, Hevia V, Rodr\u00edguez Faba O, Zakri RH (2022) EAU Guidelines on renal transplantation. EAU Guidelines Office, Amsterdam"},{"issue":"4","key":"2296_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5500\/wjt.v2.i4.51","volume":"2","author":"HV Kalluri","year":"2012","unstructured":"Kalluri HV, Hardinger KL (2012) Current state of renal transplant immunosuppression: present and future. World J Transplant 2(4):51\u201368. https:\/\/doi.org\/10.5500\/wjt.v2.i4.51","journal-title":"World J Transplant"},{"issue":"1","key":"2296_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1345\/aph.1Q537","volume":"46","author":"VC Su","year":"2012","unstructured":"Su VC, Harrison J, Rogers C, Ensom MH (2012) Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother 46(1):57\u201367. https:\/\/doi.org\/10.1345\/aph.1Q537","journal-title":"Ann Pharmacother"},{"key":"2296_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010699.pub2","volume":"11","author":"P Masson","year":"2014","unstructured":"Masson P, Henderson L, Chapman JR, Craig JC (2014) Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 11:CD010699. https:\/\/doi.org\/10.1002\/14651858.CD010699.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2296_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.942665","volume":"9","author":"Y Lombardi","year":"2022","unstructured":"Lombardi Y, Fran\u00e7ois H (2022) Belatacept in kidney transplantation: what are the true benefits? A systematic review. Front Med (Lausanne) 9:942665. https:\/\/doi.org\/10.3389\/fmed.2022.942665","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"2296_CR7","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1097\/tp.0000000000001589","volume":"101","author":"JB Cohen","year":"2017","unstructured":"Cohen JB, Eddinger KC, Forde KA, Abt PL, Sawinski D (2017) Belatacept compared with tacrolimus for kidney transplantation: a propensity score matched cohort study. Transplantation 101(10):2582\u20132589. https:\/\/doi.org\/10.1097\/tp.0000000000001589","journal-title":"Transplantation"},{"issue":"12","key":"2296_CR8","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1681\/asn.2021050628","volume":"32","author":"K Budde","year":"2021","unstructured":"Budde K, Prashar R, Haller H, Rial MC, Kamar N, Agarwal A, de Fijter JW, Rostaing L, Berger SP, Djamali A, Leca N, Allamassey L, Gao S, Polinsky M, Vincenti F (2021) Conversion from calcineurin inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial. J Am Soc Nephrol 32(12):3252\u20133264. https:\/\/doi.org\/10.1681\/asn.2021050628","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2296_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1097\/tp.0000000000002192","volume":"102","author":"A Darres","year":"2018","unstructured":"Darres A, Ulloa C, Brakemeier S, Garrouste C, Bestard O, Del Bello A, Sberro Soussan R, D\u00fcrr M, Budde K, Legendre C, Kamar N (2018) Conversion to belatacept in maintenance kidney transplant patients: a retrospective Multicenter European study. Transplantation 102(9):1545\u20131552. https:\/\/doi.org\/10.1097\/tp.0000000000002192","journal-title":"Transplantation"},{"key":"2296_CR10","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000411","author":"G Divard","year":"2024","unstructured":"Divard G, Aubert O, Debiais-Deschamp C, Raynaud M, Goutaudier V, Sablik M, Sayeg C, Legendre C, Obert J, Anglicheau D, Lefaucheur C, Loupy A (2024) Long-term outcomes after conversion to a belatacept-based immunosuppression in kidney transplant recipients. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/cjn.0000000000000411","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2296_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","volume":"69","author":"JM Griny\u00f3","year":"2017","unstructured":"Griny\u00f3 JM, Del Carmen RM, Alberu J, Steinberg SM, Manfro RC, Nainan G, Vincenti F, Jones-Burton C, Kamar N (2017) Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial. Am J Kidney Dis 69(5):587\u2013594. https:\/\/doi.org\/10.1053\/j.ajkd.2016.09.021","journal-title":"Am J Kidney Dis"},{"key":"2296_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101882","volume":"80","author":"M Moein","year":"2023","unstructured":"Moein M, Dvorai RH, Li BW, Fioramonti PJ, Schilsky JB, Thankachan R, Yang C, Saidi RF, Shahbazov R (2023) Early conversion to belatacept-based immunosuppression regimen promotes improved long-term renal graft function in kidney transplant recipients. Transpl Immunol 80:101882. https:\/\/doi.org\/10.1016\/j.trim.2023.101882","journal-title":"Transpl Immunol"},{"key":"2296_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113479","author":"D Bertrand","year":"2020","unstructured":"Bertrand D, Terrec F, Etienne I, Chavarot N, Sberro R, Gatault P, Garrouste C, Bouvier N, Grall-Jezequel A, Jaureguy M, Caillard S, Thervet E, Colosio C, Golbin L, Rerolle JP, Thierry A, Sayegh J, Janbon B, Malvezzi P, Jouve T, Rostaing L, Noble J (2020) Opportunistic infections and efficacy following conversion to belatacept-based therapy after kidney transplantation: a french multicenter cohort. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9113479","journal-title":"J Clin Med"},{"issue":"6","key":"2296_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/phar.2799","volume":"43","author":"C Ye","year":"2023","unstructured":"Ye C, Li J, Liu X, Yan J, Chen J, Wang C, Huang M, Chen X, Tang K, Chen P (2023) The incidence of cytomegalovirus and BK polyomavirus infections in kidney transplant patients receiving mTOR inhibitors: A systematic review and meta-analysis. Pharmacotherapy 43(6):552\u2013562. https:\/\/doi.org\/10.1002\/phar.2799","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2296_CR15","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, Moore N (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26(8):954\u2013962. https:\/\/doi.org\/10.1002\/pds.4233","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 4","key":"2296_CR16","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, Maura G, Caillol H, Tajahmady A, Coste J, Gissot C, Weill A, Fagot-Campagna A (2017) Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev Epidemiol Sante Publique 65(Suppl 4):S149\u2013S167. https:\/\/doi.org\/10.1016\/j.respe.2017.05.004","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2296_CR17","unstructured":"Agence de la Biom\u00e9dicine. Rapport m\u00e9dical et scientifique 2020. Saint-Denis La Plaine; 2021. https:\/\/rams-archives2020.agence-biomedecine.fr\/greffe-renale-0."},{"key":"2296_CR18","doi-asserted-by":"publisher","first-page":"S295","DOI":"10.1016\/j.respe.2022.09.035","volume":"70","author":"D Anglicheau","year":"2022","unstructured":"Anglicheau D, Bardoulat I, Arnaud M, Fouad F, Bregman B, Cott\u00e9 F-E, Vadanici R, Durrbach A, Glotz D (2022) Utilisation de l\u2019Echantillon G\u00e9n\u00e9raliste des B\u00e9n\u00e9ficiaires (EGB) pour d\u00e9crire les modalit\u00e9s de prescription des traitements immunosuppresseurs chez les transplant\u00e9s r\u00e9naux en France. Rev \u00c9pid\u00e9miol Sant\u00e9 Publique 70:S295","journal-title":"Rev \u00c9pid\u00e9miol Sant\u00e9 Publique"},{"issue":"10","key":"2296_CR19","doi-asserted-by":"publisher","first-page":"e709","DOI":"10.1016\/s2468-2667(21)00200-0","volume":"6","author":"O Aubert","year":"2021","unstructured":"Aubert O, Yoo D, Zielinski D, Cozzi E, Cardillo M, D\u00fcrr M, Dom\u00ednguez-Gil B, Coll E, Da Silva MI, Sallinen V, Lemstr\u00f6m K, Midtvedt K, Ulloa C, Immer F, Weissenbacher A, Vallant N, Basic-Jukic N, Tanabe K, Papatheodoridis G, Menoudakou G, Torres M, Soratti C, Hansen Krogh D, Lefaucheur C, Ferreira G, Silva HT Jr, Hartell D, Forsythe J, Mumford L, Reese PP, Kerbaul F, Jacquelinet C, Vogelaar S, Papalois V, Loupy A (2021) COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health 6(10):e709\u2013e719. https:\/\/doi.org\/10.1016\/s2468-2667(21)00200-0","journal-title":"Lancet Public Health"},{"issue":"8","key":"2296_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.18502\/ijph.v50i8.6801","volume":"50","author":"M Ghelichi-Ghojogh","year":"2021","unstructured":"Ghelichi-Ghojogh M, Ghaem H, Mohammadizadeh F, Vali M, Ahmed F, Hassanipour S, Nikbakht HA, Rezaei F, Fararouei M (2021) Graft and patient survival rates in kidney transplantation, and their associated factors: a systematic review and meta-analysis. Iran J Public Health 50(8):1555\u20131563. https:\/\/doi.org\/10.18502\/ijph.v50i8.6801","journal-title":"Iran J Public Health"},{"issue":"4","key":"2296_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.nephro.2017.11.006","volume":"14","author":"P Tuppin","year":"2018","unstructured":"Tuppin P, Bessou A, Legeai C, Vigneau C, Couchoud C (2018) Two-year management after renal transplantation in 2013 in France: input from the French national health system database. Nephrol Ther 14(4):207\u2013216. https:\/\/doi.org\/10.1016\/j.nephro.2017.11.006","journal-title":"Nephrol Ther"},{"issue":"3","key":"2296_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14531","volume":"36","author":"G Karadkhele","year":"2022","unstructured":"Karadkhele G, Duneton C, Garro R, Badell IR, Pearson TC, Larsen CP, Hogan J (2022) Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States. Clin Transplant 36(3):e14531. https:\/\/doi.org\/10.1111\/ctr.14531","journal-title":"Clin Transplant"},{"issue":"10","key":"2296_CR23","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1097\/tp.0000000000004254","volume":"106","author":"AO G\u00e9rard","year":"2022","unstructured":"G\u00e9rard AO, Barbosa S, Anglicheau D, Couzi L, Hazzan M, Thaunat O, Blancho G, Caillard S, Sicard A (2022) Association between maintenance immunosuppressive regimens and COVID-19 mortality in kidney transplant recipients. Transplantation 106(10):2063\u20132067. https:\/\/doi.org\/10.1097\/tp.0000000000004254","journal-title":"Transplantation"},{"issue":"8 Suppl","key":"2296_CR24","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/TP.0b013e3181a05b7a","volume":"87","author":"G Stallone","year":"2009","unstructured":"Stallone G, Infante B, Grandaliano G, Gesualdo L (2009) Management of side effects of sirolimus therapy. Transplantation 87(8 Suppl):S23\u2013S26. https:\/\/doi.org\/10.1097\/TP.0b013e3181a05b7a","journal-title":"Transplantation"},{"issue":"7","key":"2296_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.nephro.2018.03.004","volume":"14","author":"L Sitruk","year":"2018","unstructured":"Sitruk L, Couchoud C, Hourmant M, Tuppin P, Macher MA, Legeai C (2018) Description of immunosuppressive maintenance treatments post kidney transplant through the National System of Health Insurance. Nephrol Ther 14(7):523\u2013530. https:\/\/doi.org\/10.1016\/j.nephro.2018.03.004","journal-title":"Nephrol Ther"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02296-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:58:57Z","timestamp":1777564737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/4\/1229\/8457111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["2296"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02296-4","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DA has received consultancy fees from Astellas, Astra Zeneca, BMS and Chiesi. AD and DG received consultancy fees from BMS in the context of the present study. FEC, RV and MC are employees of Bristol-Myers Squibb, the study sponsor. IB and MA are employees of IQVIA, a contract research organization that received funding from the sponsor for the operational management of the study and for data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. The study protocol was submitted and approved by the relevant ethical committee for this type of database study (\n                      Comit\u00e9 \u00c9thique et Scientifique pour les Recherches, les \u00c9tudes et les \u00c9valuations dans le domaine de la Sant\u00e9\n                      ; CESREES). Approval was obtained from the French data protection agency (\n                      Commission Nationale de l'Informatique et des Libert\u00e9s\n                      ; CNIL) with respect to the confidentiality of individual patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All procedures involving human participants adhered to the required ethical standards, and no animal studies were involved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not applicable. The study was performed on a pseudoanonymized database.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}